Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Barclays Analyst Brandon Oglenski Upgrades XPO Rating to Overweight with New Price Target of 145

Elaine Mendonca by Elaine Mendonca
March 11, 2024
in Breaking News
0
Finance_ Trading ratings today (2)
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Barclays analyst Brandon Oglenski remains bullish on XPO (NYSE:XPO) with an Overweight rating and a new price target of $145, up from $125. The increased target signifies Oglenski’s optimistic view on the company’s future prospects as of March 11, 2024.

XPO Stock Price Drops 4.33% on March 11, 2024: Investors Optimistic About Future Performance

On March 11, 2024, XPO stock experienced a significant drop in price, decreasing by $5.54 or 4.33% since the market last closed. This decline brought the stock price down to $122.43. Despite the drop in price during regular trading hours, XPO stock showed some signs of recovery in pre-market trading, rising by $0.07. This slight increase may indicate that investors are feeling more optimistic about the stock’s future performance. Investors should conduct thorough research and consider their own financial goals before making any investment decisions. Overall, the performance of XPO stock on March 11, 2024, highlights the volatility of the market and the importance of staying informed and vigilant as an investor. Keep an eye on future developments to see how XPO stock continues to perform in the coming days and weeks.

XPO Logistics Financial Performance Decline Raises Concerns: Whats Next?

XPO Logistics has been facing challenges in its financial performance recently. On March 11, 2024, the company reported total revenue of $7.74 billion for the past year, which remained flat compared to the previous year. The total revenue for the fourth quarter of the year was $1.94 billion, showing no growth compared to the previous quarter.

One concerning aspect is the decline in net income. The company reported a net income of $189.00 million for the past year, a 19.92% decrease from the previous year. In the fourth quarter, the net income further decreased to $58.00 million, marking a 32.56% decline from the previous quarter.

Earnings per share (EPS) also saw a significant decrease. The company reported an EPS of $1.60 for the past year, representing a 21.27% decrease from the previous year. In the fourth quarter, the EPS further declined to $0.48, marking a 31.53% decrease from the previous quarter.

These financial indicators raise concerns about XPO Logistics’ ability to maintain profitability and growth in the future. It will be important for XPO to address the factors contributing to these declines and implement strategies to improve its financial performance in order to regain investor confidence.

Tags: XPO
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Sam Edelmans SpringSummer 2024 Campaign Featuring Kylie Jenner Celebrating 20 Years of Style

Cleanest energy and ev

Uranium Energy Corp Reports Decline in Quarterly Financial Performance

Lexicon Pharmaceuticals to Resubmit NDA for Sotagliflozin as Complement to Insulin Treatment for Type 1 Diabetes

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com